Immunomodulatory peptide

0 marketed 2 in Phase 3

This page covers all Immunomodulatory peptide drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting IL-2 pathway / T-cell activation.

Targets

IL-2 pathway / T-cell activation

Phase 3 pipeline (2)

Thymosin-α1 · Sun Yat-sen University · Immunology / Oncology
Thymosin-α1 is an immunomodulatory peptide that enhances T-cell maturation and immune function by promoting thymic development and activating innate and adaptive immunity.
IM862 · Cytran · Oncology
IM862 is an immunomodulatory agent that enhances immune function through interleukin-2 (IL-2) pathway activation.